Clinical Trials Logo

Clinical Trial Summary

This multicenter phase 2 clinical trial is designed to assess safety of P28GST (protein 28 Kd glutathion S Transferrase), aiming to control inflammation in moderate Crohn's Disease (CD), before or after intestinal resection surgery. P28GST is a parasite enzyme molecule from Schistosoma with potent immunogenic and anti-oxidant properties. Based on experimental evidence of its anti-inflammatory properties, the investigators hypothesized that administration of P28GST could protect against recurrence after intestinal resection surgery in CD.


Clinical Trial Description

To carry out this study, 24 moderate CD patients will be enrolled in a safety phase 2a study. CD patients will be included after intestinal resection surgery or in moderate Crohn's Disease (CD). Drug therapy will consisted in 3 injections of 100 µg of P28GST within 3 months (one injection per month). The main objective of this study is to follow-up monthly rate and seriousness of adverse events during one year. Secondary objectives are to control immunologic and inflammatory blood and tissue markers, appearance or not of a clinical recurrence assessed by CDAI (Crohn Disease Activity Index). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02281916
Study type Interventional
Source University Hospital, Lille
Contact
Status Completed
Phase Phase 2
Start date March 2014
Completion date February 2018

See also
  Status Clinical Trial Phase
Recruiting NCT04266600 - Extended Mesenteric Excision in Ileocolic Resections for Crohn's Disease N/A
Recruiting NCT04539665 - Extended Mesenteric Excision in Ileocolic Resections for Crohn's Disease. N/A
Recruiting NCT04623476 - PAtophysiological, Nodal-based Approach for Crohn's Disease Excision N/A
Recruiting NCT05246917 - Comparing Manual Versus Stapled Side to Side Ileocolic Anastomosis in Crohn's Disease N/A
Recruiting NCT04100005 - A Pilot Study to Explore the Role of Gut Flora in Crohn's Disease
Not yet recruiting NCT05332639 - Personalized Risk Estimation for Crohn's Disease (PRE-CD): Implementation and Feasibility N/A